Premium
Cognition Therapeutics Inc (CGTX)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an o... Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1858 | -30.5592105263 | 0.608 | 0.6154 | 0.418 | 9157086 | 0.4948129 | CS |
| 4 | -0.36005 | -46.0274848194 | 0.78225 | 0.791437 | 0.418 | 2941368 | 0.5204136 | CS |
| 12 | 0.0322 | 8.25641025641 | 0.39 | 1.29 | 0.378 | 8279736 | 0.59663618 | CS |
| 26 | -0.2697 | -38.9796213326 | 0.6919 | 1.29 | 0.34 | 4311772 | 0.57013268 | CS |
| 52 | -1.5678 | -78.783919598 | 1.99 | 3.44 | 0.34 | 2443581 | 0.66766066 | CS |
| 156 | -2.4878 | -85.4914089347 | 2.91 | 6.2686 | 0.34 | 926805 | 0.90015403 | CS |
| 260 | -11.7278 | -96.5251028807 | 12.15 | 13.8 | 0.34 | 833231 | 1.01539859 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
